Solid report...
Some quotes;
As we move towards product commercialization, we haveput in place a formal program to substantially broaden andcomplement the makeup of the Board.
Remestemcel-L has a fast track designation whichshould facilitate an expedited review by the FDA.
In Japan, revenues from sales of TEMCELL®1 HS Inj. foraGVHD by our licensee JCR Pharmaceuticals significantlyincreased during the past year. T
for Chronic Back Pain;
Enrollment in the 404-patientPhase 3 trial was completed earlier this year. If the Phase 3results confirm the earlier beneficial and sustained effects seenin Phase 2 from a single injection of MPC-06-ID on pain andfunction in these patients, we have the potential to make amajor impact on this public health emergency by providingan effective non-opioid alternative.
Make no mistake, MSB is the real deal...
Ann: Annual Report to shareholders, page-2
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
-0.010(0.76%) |
Mkt cap ! $1.495B | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.33 | $1.28 | $1.819M | 1.396M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 29972 | $1.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 2008 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |